Eli Lilly announced the results of its 1,000-person, NIH-sponsored trial on Monday. A combination of its anti-inflammatory drug, barcitinib, and the antiviral may shorten hospital stays for COVID-19 patients.
from Articles | Mail Online https://ift.tt/3muc0th
No comments:
Post a Comment